Works about CETUXIMAB
Results: 1676
Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial–mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
- Published in:
- Veterinary & Comparative Oncology, 2024, v. 22, n. 1, p. 149, doi. 10.1111/vco.12943
- By:
- Publication type:
- Article
Enzyme‐Linked DNA Displacement (ELIDIS) Assay for Ultrasensitive Electrochemical Detection of Antibodies**.
- Published in:
- Angewandte Chemie, 2024, v. 136, n. 1, p. 1, doi. 10.1002/ange.202314818
- By:
- Publication type:
- Article
Erlotinib and gefitinib responsiveness in head and neck cancer cell lines-a comparing analysis with cetuximab.
- Published in:
- Clinical Oral Investigations, 2016, v. 20, n. 4, p. 759, doi. 10.1007/s00784-015-1566-5
- By:
- Publication type:
- Article
Inhibition of N-acetylglucosaminyltransferase V enhances the cetuximab-induced radiosensitivity of nasopharyngeal carcinoma cells likely through EGFR N-glycan alterations.
- Published in:
- Glycobiology, 2017, v. 27, n. 8, p. 713, doi. 10.1093/glycob/cwx046
- By:
- Publication type:
- Article
EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans.
- Published in:
- Glycobiology, 2015, v. 25, n. 10, p. 1053, doi. 10.1093/glycob/cwv047
- By:
- Publication type:
- Article
Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
- Published in:
- PeerJ, 2024, p. 1, doi. 10.7717/peerj.17391
- By:
- Publication type:
- Article
Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study.
- Published in:
- ENT Updates, 2016, v. 6, n. 3, p. 105, doi. 10.2399/jmu.2016003005
- By:
- Publication type:
- Article
DPYD Variants as Predictors of 5-fluorouraciltoxicity in Adjuvant colon cancer treatment (NcctG N0147).
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 12, p. 1, doi. 10.1093/jnci/dju298
- By:
- Publication type:
- Article
New Therapy Targets Resistant Non-Small-Cell Lung Cancers.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 11, p. 1, doi. 10.1093/jnci/dju393
- By:
- Publication type:
- Article
mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 9, p. 1, doi. 10.1093/jnci/dju215
- By:
- Publication type:
- Article
A New Predictive Molecular Marker for Cetuximab Benefit in Rectal Cancer?
- Published in:
- 2014
- By:
- Publication type:
- Editorial
TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 7, p. 1, doi. 10.1093/jnci/dju121
- By:
- Publication type:
- Article
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 8, p. 674, doi. 10.1093/jnci/djr070
- By:
- Publication type:
- Article
Response: Re: How Much Is Life Worth: Cetuximab, Non–Small Cell Lung Cancer, and the $440 Billion Question.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 15, p. 1207, doi. 10.1093/jnci/djq247
- By:
- Publication type:
- Article
StatBite: Radiation Therapy Plus Cetuximab: skin Reactions from 71 Head and Neck Cancer Patients from 11 Institutions in Europe.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 2, p. 75, doi. 10.1093/jnci/djp532
- Publication type:
- Article
Should Cetuximab Replace Cisplatin in Head and Neck Cancer?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 2, p. 74, doi. 10.1093/jnci/djp531
- By:
- Publication type:
- Article
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 19, p. 1308, doi. 10.1093/jnci/djp280
- By:
- Publication type:
- Article
IN THIS ISSUE.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 17, p. 1159, doi. 10.1093/jnci/djp289
- Publication type:
- Article
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 17, p. 1182, doi. 10.1093/jnci/djp232
- By:
- Publication type:
- Article
Cost Effectiveness Ratio for Cetuximab More Favorable in Metastatic Colorectal Casncer Patients With Wild-type KRAS Tumors.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 17, p. 1159, doi. 10.1093/jnci/djp295
- Publication type:
- Article
Challenges and Opportunities for Use of Cost-Effectiveness Analysis.
- Published in:
- 2009
- By:
- Publication type:
- Editorial
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 15, p. 1044, doi. 10.1093/jnci/djp177
- By:
- Publication type:
- Article
K-Ras Mutations Are Changing Practice in Advanced Colorectal Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 23, p. 1667, doi. 10.1093/jnci/djn429
- By:
- Publication type:
- Article
In Brief.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2006, v. 98, n. 7, p. 438, doi. 10.1093/jnci/djj150
- Publication type:
- Article
Cetuximab Therapy and Symptomatic Hypomagnesemia.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 16, p. 1221, doi. 10.1093/jnci/dji242
- By:
- Publication type:
- Article
Differential Effects of Gefitinib and Cetuximab on Non—small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 16, p. 1185, doi. 10.1093/jnci/dji238
- By:
- Publication type:
- Article
Gefitinib Versus Cetuximab in Lung Cancer: Round One.
- Published in:
- 2005
- By:
- Publication type:
- Editorial
Gene Copy Number May Be Associated With Response to EGFR Inhibitors.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 10, p. 712
- By:
- Publication type:
- Article
In Brief.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2004, v. 96, n. 6, p. 432, doi. 10.1093/jnci/96.6.432
- By:
- Publication type:
- Article
The chromatin remodeler CHD6 promotes colorectal cancer development by regulating TMEM65-mediated mitochondrial dynamics via EGF and Wnt signaling.
- Published in:
- Cell Discovery, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41421-022-00478-z
- By:
- Publication type:
- Article
Cetuximab and Other Anti--Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer.
- Published in:
- Oncologist, 2009, v. 14, n. 6, p. 601, doi. 10.1634/theoncologist.2008-0153
- By:
- Publication type:
- Article
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2009, v. 14, n. 5, p. 478, doi. 10.1634/theoncologist.2008-0202
- By:
- Publication type:
- Article
ERRATUM.
- Published in:
- 2009
- By:
- Publication type:
- Correction Notice
Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies.
- Published in:
- Oncologist, 2009, v. 14, n. 2, p. 119, doi. 10.1634/theoncologist.2008-0124
- By:
- Publication type:
- Article
Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?
- Published in:
- Oncologist, 2009, v. 14, n. 1, p. 29, doi. 10.1634/theoncologist.2008-0167
- By:
- Publication type:
- Article
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice.
- Published in:
- Oncologist, 2008, v. 13, n. 12, p. 1270, doi. 10.1634/theoncologist.2008-0181
- By:
- Publication type:
- Article
Chemotherapy for Colorectal Cancer Liver Metastases.
- Published in:
- Oncologist, 2008, v. 13, n. 10, p. 1063, doi. 10.1634/theoncologist.2008-0142
- By:
- Publication type:
- Article
Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes.
- Published in:
- Oncologist, 2008, v. 13, n. 8, p. 899, doi. 10.1634/theoncologist.2007-0157
- By:
- Publication type:
- Article
Chemotherapy in Elderly Patients with Colorectal Cancer.
- Published in:
- Oncologist, 2008, v. 13, n. 4, p. 390, doi. 10.1634/theoncologist.2007-0043
- By:
- Publication type:
- Article
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways.
- Published in:
- Oncologist, 2008, v. 13, n. 3, p. 289, doi. 10.1634/theoncologist.2007-0134
- By:
- Publication type:
- Article
Administration of Cetuximab Every 2 Weeks in the Treatment of Metastatic Colorectal Cancer: An Effective, More Convenient Alternative to Weekly Administration?
- Published in:
- Oncologist, 2008, v. 13, n. 2, p. 113, doi. 10.1634/theoncologist.2007-0201
- By:
- Publication type:
- Article
Synergy Between Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract.
- Published in:
- Oncologist, 2008, v. 13, n. 1, p. 1, doi. 10.1634/theoncologist.2006-0049
- By:
- Publication type:
- Article
Update on Capecitabine in Colorectal Cancer.
- Published in:
- Oncologist, 2006, v. 11, n. 9, p. 1003, doi. 10.1634/theoncologist.11-9-1003
- By:
- Publication type:
- Article
New Modalities to Treat Laryngeal Cancer.
- Published in:
- Collegium Antropologicum, 2012, v. 36, p. 3
- By:
- Publication type:
- Article
Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control.
- Published in:
- 2024
- By:
- Publication type:
- Letter
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells.
- Published in:
- Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-85856-9
- By:
- Publication type:
- Article
Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-80283-8
- By:
- Publication type:
- Article
Evaluation of peripheral blood inflammation indexes as prognostic markers for colorectal cancer metastasis.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-68150-y
- By:
- Publication type:
- Article
First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-65474-7
- By:
- Publication type:
- Article
Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 11, p. 1647, doi. 10.3390/biom13111647
- By:
- Publication type:
- Article